GlassScriptPhysician profile
Lorven Michael Edralin
NPI 1316385982
$2,494.88
in general payments reported to CMS, 2019-2025
24 companies · $644 in 2025
The $644 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $124 · 2021: $212 · 2022: $154 · 2023: $372 · 2024: $620 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $565.51 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $335.37 | 2023-2024 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $225.24 | 2024-2025 | |
| Cranial Technologies, INC | $197.37 | 2019-2025 | Doc Band |
| Corium, LLC | $161.25 | 2022-2025 | Azstarys |
| Sanofi Pasteur INC. | $142.89 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $127.82 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Verrica Pharmaceuticals INC. | $96.47 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $89.29 | 2023-2024 | Flumist Quadrivalent |
| Novartis Pharmaceuticals Corporation | $88.97 | 2019 | |
| Collegium Pharmaceutical, INC. | $87.91 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $85.27 | 2023-2025 | Bexsero, Pediarix, Boostrix |
| Ars Pharmaceuticals Operations, INC. | $46.80 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $42.59 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $39.00 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $24.39 | 2025 | Neffy |
| Photonicare INC | $22.90 | 2025 | Otosight Middle Ear Scope |
| Rhythm Pharmaceuticals, INC. | $19.32 | 2025 | Imcivree |
| Genzyme Corporation | $18.95 | 2022 | |
| Lnhc, INC | $16.43 | 2025 | Zelsuvmi |
| Aytu Biopharma, INC. | $16.28 | 2024 | Karbinal |
| Phadia US INC. | $15.99 | 2024 | Immunocap |
| Tris Pharma INC | $14.78 | 2024 | Dyanavel Xr |
| Becton, Dickinson and Company | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorven Edralin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.